Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction  by Kaplan, Mehmet et al.
Detection of Chlamydia pneumoniae and
Helicobacter pylori in atherosclerotic plaques of
carotid artery by polymerase chain reaction
Mehmet Kaplan a,*, Serap Simsek Yavuz b, Bayer Cinar a,
Vedat Koksal c, Mustafa Sinan Kut a, Fikri Yapici a,
Hakan Gercekoglu a, Mahmut Murat Demirtas a
International Journal of Infectious Diseases (2006) 10, 116—123
http://intl.elsevierhealth.com/journals/ijidaDepartment of Cardiovascular Surgery, Siyami Ersek Thoracic and Cardiovascular
Surgery Center, Istanbul, Turkey
bDepartment of Infectious Diseases and Clinical Microbiology, Siyami Ersek Thoracic
and Cardiovascular Surgery Center, Istanbul, Turkey
cDepartment of Histology and Embryology, Siyami Ersek Thoracic and Cardiovascular
Surgery Center, Istanbul, Turkey
Received 13 May 2004; received in revised form 13 August 2004; accepted 22 October 2004







Objectives: A possible role of some microorganisms has been proposed in the
pathogenesis of atherosclerosis, but it is still an unresolved issue. We investigated
the presence of Chlamydia pneumoniae and Helicobacter pylori DNA in carotid artery
atherosclerotic plaques by using PCR.
Methods: One hundred and four patients with atherosclerotic diseases were
included. The study group consisted of 52 atherosclerotic plaque specimens obtained
from the carotid arteries of patients who had carotid endarterectomy and the control
group consisted of 52 specimens obtained from the macroscopically healthy regions of
ascending aorta in patients who had undergone coronary artery bypass grafting. The
presence of C. pneumoniae and H. pylori DNA in endarterectomy specimens were
demonstrated by PCR.
Results: C. pneumoniae DNAwas detected in 16 of 52 (30.8%) atherosclerotic plaques
and 1 of 52 (1.9%) macroscopically healthy ascending aorta wall specimens
(P < 0.001). H. pylori DNA was detected in 9 of 52 (17.3%) atherosclerotic plaques
and none of the controls (P = 0.003).* Corresponding author. Tel.: +90 216 455 74 52; fax: +90 216 348 93 23.
E-mail address: mehmetkaplan@superonline.com (M. Kaplan).
1201-9712/$32.00 # 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Atherosclerosis is defined as a chronic inflamma-
tory disease. Risk factors in the formation, pro-
gression and destabilization of atherosclerotic
plaques, including family history, hyperlipidemia,
hypertension, diabetes mellitus, sex and smoking
habits, cannot completely explain the pathogen-
esis of atherosclerosis, but only clarify some of its
aspects.1
Recent data suggest a causative role for one or
more infectious agents in some chronic inflammatory
diseases such as duodenal ulcer, chronic respiratory
diseases (including asthma) and atherosclerotic dis-
eases.2 The causal role of infectious agents in chronic
inflammatory diseases and their association with
these conditions have major implications related to
public health, treatment and prevention. Chlamydia
pneumoniae and Helicobacter pylori are among the
most commonly implicated microorganisms in the
pathogenesis of atherosclerosis.3,4
In this study, the presence of C. pneumoniae DNA
and H. pylori DNAwas investigated in carotid endar-
terectomy plaques and healthy ascending aorta wall
specimens by polymerase chain reaction (PCR). Ser-
oepidemiological findings are discussed in the light
of the literature.Methods
Study population
One hundred and four patients admitted to the
Siyami Ersek Thoracic and Cardiovascular Surgery
Center for surgery for atherosclerotic carotid or
coronary artery disease between July 2000 and
December 2001 were included in the study. Fifty-
two atherosclerotic carotid plaque specimens from
cases who had carotid endarterectomy constituted
the study group (36 male, 16 female, mean age
67.5  7.8) and 52 specimens from macroscopically
healthy regions of the ascending aorta of cases who
underwent coronary artery bypass grafting consti-
tuted the control group (38 male, 14 female, mean
age 62.1  8.6). Patients in the control group under-
went operations for coronary artery disease, had no
carotid atherosclerotic disease and the ascendingaorta of these patients was macroscopically healthy.
All patients in the study group were symptomatic
and had carotid artery stenosis greater than 70%.
Preoperative demographic characteristics and risk
factors of cases were recorded. Risk factors for
atherosclerosis including hypertension, diabetes
mellitus, lipid profile, smoking habits, previous
myocardial infarction and other medical history
were recorded for each patient in both the study
and the control groups.
Common risk factors for patients in the study and
control groups are summarized in Table 1. Forty
patients in the study group had only carotid endar-
terectomy, while 12 patients had both carotid
endarterectomy and coronary artery bypass grafting
operations. All 52 patients in the control group had
aortocoronary bypass grafting operations.
Specimen collection
The specific recommendations of the Centers for
Disease Control and Prevention (USA) and the
Laboratory Centre for Disease Control (Canada)
for PCR of C. pneumoniae were followed during
the collection, transport, processing and assaying
of specimens.5
All of the specimens were obtained in the oper-
ating room under sterile conditions. Carotid artery
atherosclerotic plaque specimens of approximately
0.5—1 cm were placed into Eppendorf tubes con-
taining Tris—EDTA buffer. Eppendorf tubes were
labeled in the operating room. The microbiologists
were blind with respect to the relevant groups
(study and control) of specimens.
Specimen transport and processing
All of the specimens were sent to the laboratory and
processed within 24 h; they were stored and trans-
ported at +4 8C. Calcified areas of vascular tissue
specimens which are known PCR inhibitors were
removed and the rest of the specimens were cut
into small pieces (25 mg) and processed for DNA
extraction. All tissue samples were processed for
PCR by proteinase potassium digestion, phenol—
chloroform extraction, and ethanol precipitation.
DNA extracts were formed into aliquots to avoid >1
freeze—thaw cycle for optimal yields.5Conclusions: The higher incidence of C. pneumoniae and H. pylori DNA in athero-
sclerotic plaques suggests that these microorganisms may play a role in the pathogen-
esis of atherogenesis.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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Table 1 The demographic data of the patients in the study and control groups.
Characteristics Study group (n = 52) Control group (n = 52) P Valuea
Mean ageb 67.46  7.84 62.08  8.62
Sex 0.665
Female 16 (30.77%) 14 (26.92%)
Male 36 (69.23%) 38 (73.08%)
Smoking habit 22 (42.31%) 21 (40.38%) 0.842
COPD 7 (13.46%) 3 (5.77%) 0.178
Coronary artery disease 25 (48.08%) 52 (100%);
(group characteristic)
<0.001
Peripheral artery disease 5 (9.62%) 8 (15.38%) 0.372
Hypertension 39 (75%) 30 (57.69%) 0.061
Hypercholesterolemia 20 (38.46%) 18 (34.61%) 0.684
Total cholesterol level (mg/dL) 228  48.12 239  49.19 0.252
Obesity 5 (9.62%) 6 (11.54%) 0.750
Diabetes mellitus 10 (19.23%) 15 (28.85%) 0.250
Combination of risk factors
Smoking + hypertension 16 (30.77%) 9 (17.31%) 0.106
Smoking + hypercholesterolemia 9 (17.31%) 2 (3.85%) 0.021
Smoking + hypertension + hypercholesterolemia 3 (5.77%) 1 (1.92%) 0.618
COPD, chronic obstructive pulmonary disease.
a P < 0.05 is significant.
b Mean  standard deviation.PCR amplification
DNA was amplified in 50 ml volumes containing
200 mM each deoxynucleoside triphosphate (dNTP)
(MBI Fermentas, Burlington, Ontario, Canada), 2 mM
of each primer, 2 U Taq polymerase (MBI Fermen-
tas), 10 mM Tris—HCL, 50 mM KCl, 1.5 mM MgCl2.
Reaction tubes were placed in a thermal cycler
(PTC-150 MJ Research, Waltham, MA, USA). Globulin
primers were included in the assay as internal posi-
tive controls. Two positive and two negative controls
were included in each assay as mix control.
The primer sequences, conditions, and size of
these PCR methods are summarized in Table 2 for
C. pneumoniae5,6,7 and Table 3 for H. pylori.8 For
the detection of C. pneumoniae by PCR, two differ-
ent PCR assays were done with two different sets of
primers (Table 2).
Amplification products, 437—463 bp for C. pneu-
moniae and 294 bp for H. pylori were visualized by
electrophoresis in a 2% agarose gel containing ethi-Table 2 PCR assays for Chlamydia pneumoniae.
PCR target gene, and
size of PCR products
Primer names and sequences
(1) Cloned PstI, 437 bp HL1 : 50 gtt gtt cat gaa ggc cta
HR1 : 50 tgc ata acc tac ggt gt
(2) 16S rRNA, 463 bp CpnA : 50 tga caa ctg tag aaa t
CpnB : 50 cgc ctc tct cct ata adium bromide. Tissue preparation, PCR amplifica-
tion, and electrophoresis were performed in
separate rooms, to avoid the risk of contamination.
Statistical analyses
Statistical analyses were carried out using SPSS 10.0
(SPSS Inc, Chicago, IL, USA) and MATLAB 6.0.88
Release 12 (The MathWorks, Inc, Boston, MA,
USA). Data are expressed as mean  standard devia-
tion. A P value of less than 0.05 was considered to
indicate statistical significance.
When statistically comparing the demographic
data of the study and control groups, the Likelihood
Ratio test and Fisher’s Exact test based on the com-
parison of independent group ratios were used for
sex, smoking habit, chronic obstructive pulmonary
disease, coronary artery disease, peripheral artery
disease, hypertension, hypercholesterolemia, obe-
sity, diabetes mellitus, history of transient ischemic
attack and unstable angina pectoris. For cholesterolPCR conditions and size of PCR products
ct 30 94 8C-45 s, 48 8C-30 s, 72 8C-30 s
g tt 30 (40 cycles)
ac agc 30 94 8C-1 min, 45 8C -30 s, 72 8C-30 s
at 30 (40 cycles)
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Table 3 PCR assay for Helicobacter pylori.
PCR Target gene, and
size of PCR products
Primer names and sequences PCR conditions
glmM gene, 294 bp Forward, 50 — aag ctt tta ggg gtg tta ggg gtt 30 93 8C-1 min,
55 8C-1 min,
Reverse, 50 — aag ctt act ttc taa cac taa cgc 30 72 8C-1 min
(35 cycles)levels, the Independent-Samples T test based on the
comparison of independent two group means was
used and homogeneity of cholesterol level variances
were tested using Levene’s f test. The Pearson Chi-
square test and Odds Ratio (OR) test were used to
investigate the probability of the presence of certain
personal and environmental features in the study
group patients with positive C. pneumoniae and H.
pylori. Significance of OR values were tested by the
calculation of 95% confidence interval (CI) limits and
ranges not including ‘1’ value were considered to be
statistically significant (P < 0.05).
Results
The demographic data of the patients in the study
group and the control group are shown in Table 1. No
significant differences were found between the
two groups with respect to age, sex and known
risk factors (smoking habits, chronic obstructive
pulmonary disease, peripheral artery disease,
hypertension, hypercholesterolemia, obesity and
diabetes mellitus).
Successful genomic DNA extraction was tested
using globulin gene primers (data not shown). The
extraction was performed a second time for three
of the 104 samples to get DNA for successful ampli-
fication. The assay was validated using samplesFigure 1 Amplification of cloned PstI gene of the Chlamy
Helicobacter pylori. (+) control (C. pneumoniae): Lane 1; C.
pylori): Lane 4; H. pylori (+) patients: Lanes 5 and 8; () copreviously found positive for H. pylori or C. pneu-
moniae. The presence of C. pneumoniae was tested
using two sets of primers and we observed complete
concordance between methods. Two previously
known positive and two negative controls were
included in each assay as mix control against any
PCR inhibitors or false positive amplification.
In the study group, the C. pneumoniae positivity
rate was 30.77% (16 patients), whereas the H. pylori
positivity rate was 17.31% (9 patients) (see Figures 1
and 2). However, in the control group, C. pneumo-
niae and H. pylori positivity rates were 1.9% and 0%,
respectively. In one case, where right and left
endarterectomies were performed separately 3
months apart, H. pylori was detected in both speci-
mens. None of the samples were positive for both C.
pneumoniae and H. pylori.
Results of the study and control groups regarding
C. pneumoniae positivity were different and the
difference was statistically significant (30.77% and
1.9% for study and control groups, respectively;
P < 0.001 (2-sided), Pearson Chi-square test). The
study and control groups also differed in terms of H.
pylori positivity and the difference was also statis-
tically significant (P = 0.003 (2-sided), Fisher’s Exact
test).
Demographic features of C. pneumoniae and H.
pylori positive cases were investigated and the
possibility of the presence of these features (Oddsdia pneumoniae and glmM (urease C gene) gene of the
pneumoniae (+) patients: Lanes 2 and 3; (+) control (H.
ntrol: Lanes 6 and 7.
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Figure 2 Amplification 16S rRNA gene of Chlamydia pneumoniae and glmM (urease C gene) gene of Helicobacter pylori.
M: Marker: 100 bp ladder (Promega); (+) control (C. pneumoniae): Lane 1; C. pneumoniae (+) patients: Lanes 2 and 3; (+)
control (H. pylori): Lane 4; H. pylori (+) patients: Lanes 5 and 6; () control: Lane 7.Ratio) were calculated according to 95% CI values
and they are shown in Table 4. Common features of
study group patients positive for C. pneumoniae in
their atheroma plaques are summarized in Table 4.
In this group, in cases with C. pneumoniae positivity,
the probability of the presence of coronary artery
disease was increased 42.8 times, and probabilities
were increased 13.6 and 3.55 times for the presence
of peripheral artery disease and diabetes mellitus
respectively, and these values were statisticallyTable 4 The demographic data of Chlamydia pneumoniae
group.
Characteristics Study group (n = 52)
CP positive HP positive









Smoking habit 7 1
COPD 3 2
Coronary artery disease 15 1




Diabetes mellitus 6 1
TIA history 8 4
Unstable angina pectoris 2 1
COPD, chronic obstructive pulmonary disease; CP, C. pneumoniae;
a Mean  standard deviation.
b 95% CI, P > 0.05.
c P < 0.05 is significant, (2-sided), Pearson Chi-square test.
d 95% CI, P < 0.05.significant (P < 0.05). Probability of chronic
obstructive pulmonary disease was increased 1.53
times, hypertension and unstable angina pectoris
2.58 times and 3.37 times, respectively, however
these were not statistically significant. Probabilities
of other features were lower and the values were
not statistically significant.
Common features of H. pylori positive patients
are summarized in Table 4. The probability of
chronic obstructive pulmonary disease was 2.02and Helicobacter pylori positive patients in the study
Odds Ratio (95% CI: lower < OR < upper)
CP HP
0.09 < 0.297 < 1.7b 0.25 < 0.90 < 5.33b
P = 0.630c P = 0.603c
0.33 < 0.66 < 3.58b 0.01 < 0.14 < 1.14b
0.36 < 1.53 < 9.42b 0.35 < 2.02 < 13.5b
4.5 < 42.8 < 335.3d 0.15 < 0.41 < 2.9b
1.18 < 13.6 < 114.9d 0.12 < 1.44 < 12.4b
0.56 < 2.58 < 15.9b 0.07 < 0.25 < 1.49b
0.11 < 0.28 < 1.54b 0.17 < 0.59 < 3.4b
0.05 < 0.62 < 5.19b 0.12 < 1.44 < 12.4b
1.13 < 3.55 < 20.5d 0.05 < 0.53 < 4.28b
0.48 < 0.95 < 5.15b 0.26 < 0.82 < 4.72b
0.14 < 3.37 < 39.8b 0.29 < 7.69 < 92.8b
HP, H. pylori; OR, Odds Ratio; TIA, transient ischemic attack.
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disease was 1.44 times higher, the probability of
obesity was 1.44 times higher and the probability of
unstable angina pectoris was 7.69 times higher,
however these were not statistically significant.
Probabilities of other features were lower but values
were not statistically significant.
Discussion
An association between infectious processes and
atherosclerosis has been reported in numerous stu-
dies in recent years.1 C. pneumoniae and H. pylori
are among the most frequently implicated micro-
organisms.3
By using the PCR method, we investigated the
presence in atherosclerotic plaques of C. pneumo-
niae, which is the most strongly implicated, and H.
pylori, a common infectious agent in our country. A
possible association between C. pneumoniae and
atherosclerosis was first demonstrated by a seroe-
pidemiological study by Saikku and colleagues in
1988.9 Shore and colleagues10 first demonstrated
the presence of C. pneumoniae in atheroma pla-
ques by using the PCR method and electron micro-
scopy. Although C. pneumoniae positivity in
atheroma plaques was demonstrated in most of
the studies which used the PCR method following
the study of Shore and colleagues, rates varied
considerably.3,10—13 The most significant cause
for this is lack of standardization with regard to
PCR methods. In a study by Apfalter and collea-
gues,14 the presence of C. pneumoniae was inves-
tigated in 15 endarterectomy specimens and each
specimen was investigated at nine different cen-
ters by PCR. C. pneumoniae positivity for each
specimen varied between 0 and 60% (intercenter
variability). Reasons for obtaining such variable
results by PCR are suggested to include patchy
distribution of C. pneumoniae in atherosclerotic
lesions, insufficient atheromatous tissue exam-
ined, lack of standardization of laboratory meth-
ods, inability to perform C. pneumoniae DNA
extraction from atheroma plaques and the pre-
sence of PCR inhibitors in atheroma plaques.15,16
In order to provide a standard for C. pneumoniae
PCR tests and to exclude possible factors that may
prevent the detection of C. pneumoniae by PCR, the
Centers for Disease Control and Prevention (USA)
and the Laboratory Centre for Disease Control
(Canada) published a guideline named ‘‘Standardiz-
ing Chlamydia pneumonaie assays’’.5 In our study,
we performed C. pneumonaie PCR according to the
recommendations of this guideline in obtaining the
specimens, transportation, extraction and for PCRprocesses and we used two of the four methods6,7
that were designated as standard in this guideline.
The C. pneumoniae positivity rate was found to be
30.77% by both of these methods. The C. pneumo-
niae positivity rate in atheroma plaques was
reported as 26% in a Turkish study, in which 16S
rRNA primers were also used.17 In a study from
Washington University, which used the other primer
of our study, the C. pneumoniae positivity rate in
carotid artery plaques was found to be 24%18 by PCR.
In a report that evaluated the results of 30 other
studies that investigated the presence of C. pneu-
moniae in atheroma plaques obtained from arterial
samples by PCR, the overall C. pneumoniae positiv-
ity rate was 25% for atheroma plaques, whereas it
was 1% or less for normal vascular tissues.15 The C.
pneumoniae positivity rate of 30.77% in carotid
atheroma plaques that we found in our study also
supports these results.
In a number of studies, some clinical features of
atherosclerosis12,19 were found to be associated
with C. pneumoniae positivity in atherosclerotic
tissues. In our study there were no differences
between C. pneumoniae positive and negative cases
with respect to these kinds of lesions. But coronary
artery disease, peripheral arterial disease and dia-
betes mellitus were found to be more frequent in C.
pneumoniae positive cases than negative cases, and
these were statistically significant (P < 0.05).
Establishing a possible causal relationship between
C. pneumoniae and these diseases from our results is
difficult and further studies concerning this subject
are required.
Another microorganism that is suggested to play
a role in the pathogenesis of atherosclerosis is H.
pylori. H. pylori is a Gram-negative, spiral bacillus;
its causal role in duodenal ulcer has been demon-
strated.2 There is not yet evidence as strong for an
association between H. pylori and atherosclerosis
as there is for C. pneumoniae. However in coun-
tries with an H. pylori prevalence of greater than
80%,20 such as Turkey, it is important to clarify this
issue. Most studies demonstrating an association
between H. pylori and atherosclerosis are serolo-
gical studies. Such an association was reported for
the first time by Mendall and colleagues.21 The high
prevalence of H. pylori infections in developing
countries (e.g. Turkey) devalues serological stu-
dies. Because H. pylori seropositivity will be above
80% in any control group, comparison with study
groups will be impossible. Therefore, in our study
we directly investigated the presence of H. pylori
in atheroma plaques by PCR. The results of
the studies investigating the presence of H. pylori
in atherosclerotic plaques by PCR are conflict-
ing.22—29 In some of these studies, the presence
122 M. Kaplan et al.of H. pylori could not be detected,22—26 whereas
in others the presence of H. pylori could be
shown.17,27—29 Standardization problems related
to PCR may have a role in the failure to detect
H. pylori in atheroma plaques by the PCR method,
as is the case for C. pneumoniae.
The glmM (urease C) primer that we used in our
study for the detection of H. pylori is currently
regarded as the most specific primer.30 In studies
where H. pylori was investigated in atheroma pla-
ques by the PCR method, positivity rates varied
between 22 and 51%.17,27—29 In our study, H. pylori
positivity in atheroma plaques was 17.31% com-
pared to 0% in healthy vascular tissues, and the
difference was statistically significant (P = 0.003).
In addition, a patient had right and left carotid
endarterectomy operations 3 months apart and
H. pylori was positive in both atheroma plaques
obtained from right and left sides, suggesting
that H. pylori causes a systemic effect on ather-
ogenesis.
Socioeconomic level is known to be associated
with H. pylori infections.31 Two of five studies which
demonstrated the presence of H. pylori (including
our study) are reported from Turkey17 and one other
from Argentina27 which is also a developing country,
suggesting that this organism may play a role in
atherosclerosis where the prevalence of this infec-
tion is high.
In our study C. pneumoniae and H. pylori were
found at a greater rate in carotid artery atheroma
plaques, compared to healthy vascular walls (for
C. pneumoniae P < 0.001; for H. pylori P = 0.003).
These results support the suggestion that both
C. pneumoniae and H. pylori have a role in the
pathogenesis of atherosclerosis.
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